Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
Search results
591 results
-
-
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: TBC
-
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]
In development [GID-TA10649] Expected publication date: 22 September 2021
-
Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: 15 December 2021
-
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]
In development [GID-TA10729] Expected publication date: TBC
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]
In development [GID-TA10708] Expected publication date: 22 December 2021
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]
In development [GID-TA10299] Expected publication date: TBC
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
In development [GID-TA10526] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]
In development [GID-TA10449] Expected publication date: TBC
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: TBC
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]
In development [GID-TA10806] Expected publication date: TBC
-
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
In development [GID-TA10805] Expected publication date: 23 March 2022
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 09 March 2022
-
Erenumab for preventing migraine [ID1188]
In development [GID-TA10302] Expected publication date: 10 March 2021
-
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]
In development [GID-TA10482] Expected publication date: TBC
-
Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613]
In development [GID-TA10532] Expected publication date: 21 April 2021
-
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]
In development [GID-TA10619] Expected publication date: TBC
-
Secukinumab for treating plaque psoriasis in children and young people [ID1669]
In development [GID-TA10554] Expected publication date: 20 October 2021
-
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]
In development [GID-TA10703] Expected publication date: 21 July 2021
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides [ID3831]
In development [GID-TA10736] Expected publication date: 05 January 2022
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 16 June 2021
-
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429
In development [GID-TA10512] Expected publication date: 22 June 2022
-
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593) [ID3755]
In development [GID-TA10675] Expected publication date: 31 March 2021
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]
In development [GID-TA10740] Expected publication date: 13 July 2022
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 14 September 2022
-
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]
In development [GID-TA10381] Expected publication date: 31 March 2021
-
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]
In development [GID-TA10644] Expected publication date: 17 March 2021
-
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]
In development [GID-TA10406] Expected publication date: 25 August 2021
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: 19 May 2021
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: 19 May 2021
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 19 May 2021
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: 31 March 2021
-
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]
In development [GID-TA10756] Expected publication date: 22 September 2021
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]
In development [GID-TA10305] Expected publication date: 31 March 2021
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: 26 May 2021
-
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
In development [GID-TA10334] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
In development [GID-TA10697] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]
In development [GID-TA10766] Expected publication date: TBC
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: TBC
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
In development [GID-TA10674] Expected publication date: TBC